Bispecific and multispecific antibodies in oncology: opportunities and challenges
ME Goebeler, G Stuhler, R Bargou - Nature Reviews Clinical Oncology, 2024 - nature.com
Research into bispecific antibodies, which are designed to simultaneously bind two antigens
or epitopes, has advanced enormously over the past two decades. Owing to advances in …
or epitopes, has advanced enormously over the past two decades. Owing to advances in …
[HTML][HTML] Revolutionizing cancer treatment: the power of bi-and tri-specific T-cell engagers in oncolytic virotherapy
A Zarezadeh Mehrabadi, M Tat… - Frontiers in …, 2024 - frontiersin.org
Bi-or tri-specific T cell engagers (BiTE or TriTE) are recombinant bispecific proteins
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …
Facile Access to Branched Multispecific Proteins
A Okon, J Yang, JLB Giancola, OJ Molina… - Bioconjugate …, 2024 - ACS Publications
Approaches that leverage orthogonal chemical reactions to generate protein–protein
conjugates have expanded access to bespoke chimeras. Although the literature is replete …
conjugates have expanded access to bespoke chimeras. Although the literature is replete …
[HTML][HTML] Revolutionizing cancer treatment: the power of bi-and tri-specific T-cell engagers in oncolytic virotherapy
AZ Mehrabadi, M Tat, AG Alvanegh… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Bi-or tri-specific T cell engagers (BiTE or TriTE) are recombinant bispecific proteins
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …
[HTML][HTML] Impact of T-Cell Engagers on COVID-19–Related Mortality in B-Cell Lymphoma Patients Receiving B-Cell Depleting Therapy
CM Lee, PG Choe, CK Kang, HJ Jo… - Cancer Research and …, 2024 - ncbi.nlm.nih.gov
Purpose B-cell depleting therapies, including T-cell engager (TCE), are increasingly used
for patients with hematologic malignancies, including during the coronavirus disease 2019 …
for patients with hematologic malignancies, including during the coronavirus disease 2019 …
[HTML][HTML] Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
X Qin, W Ning, H Liu, X Liu, W Luo, N Xia - Acta Pharmaceutica Sinica B, 2024 - Elsevier
T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated
antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor …
antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor …
Theramutein modulators
GM Housey - US Patent 11,925,647, 2024 - Google Patents
Related US Application Data continuation of application No. 16/656,271, filed on Oct. 17,
2019, now Pat. No. 10.806. 738, which is a continuation of application No. 15/789,476, filed …
2019, now Pat. No. 10.806. 738, which is a continuation of application No. 15/789,476, filed …